The incidence of kidney disease progression (≥50% decline in eGFR, ESKD, or death due to kidney-related causes) was lower with SGLT2 inhibitor treatment vs the comparator arm (2.2 vs 3.8 per 1000 person-years), with an overall 42% lower relative risk (overlap-weighted HR 0.58; 95% CI 0.48, 0.69). Here, SLC5A2 is linked to kidney disorder.